Decision algorithm for prescribing SGLT2 inhibitors and GLP-1 receptor agonists for diabetic kidney disease
Diabetic kidney disease and its comorbid conditions, including atherosclerotic
cardiovascular disease, heart failure, diabetes, and obesity, are interconnected conditions …
cardiovascular disease, heart failure, diabetes, and obesity, are interconnected conditions …
Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a …
T Yamada, M Wakabayashi, A Bhalla, N Chopra… - Cardiovascular …, 2021 - Springer
Background Emerging evidence suggests that sodium-glucose cotransporter-2 (SGLT-2)
inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with …
inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with …
Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care
Aims/hypothesis We compared the effects of sodium–glucose cotransporter 2 (SGLT2)
inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) on renal …
inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) on renal …
Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of kidney outcomes: emulation of a target trial …
OBJECTIVE To examine the comparative effectiveness of sodium–glucose cotransporter 2
inhibitors (SGLT2i), glucagon-like peptide 1 receptor agonists (GLP-1), dipeptidyl peptidase …
inhibitors (SGLT2i), glucagon-like peptide 1 receptor agonists (GLP-1), dipeptidyl peptidase …
Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis
AD Kaze, M Zhuo, SC Kim, E Patorno… - Cardiovascular diabetology, 2022 - Springer
Background We conducted a systematic review and meta-analysis of the cardiovascular,
kidney, and safety outcomes of sodium-glucose cotransporter 2 inhibitors (SGLT2i) among …
kidney, and safety outcomes of sodium-glucose cotransporter 2 inhibitors (SGLT2i) among …
Kidney and cardiovascular effectiveness of SGLT2 Inhibitors vs GLP-1 receptor agonists in type 2 diabetes
D Edmonston, H Mulder, E Lydon, K Chiswell… - Journal of the American …, 2024 - jacc.org
Background Emerging data suggest that glucagon-like peptide-1 receptor agonists (GLP-1
RAs) improve kidney outcomes for people with type 2 diabetes (T2D). Direct comparisons of …
RAs) improve kidney outcomes for people with type 2 diabetes (T2D). Direct comparisons of …
Real-life prescribing of SGLT2 inhibitors: how to handle the other medications, including glucose-lowering drugs and diuretics
D Lam, A Shaikh - Kidney360, 2021 - journals.lww.com
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have emerged as an effective therapy
for improving outcomes in diabetic and nondiabetic kidney disease (1, 2). Clinical trials have …
for improving outcomes in diabetic and nondiabetic kidney disease (1, 2). Clinical trials have …
Incorporating SGLT2i and GLP-1RA for cardiovascular and kidney disease risk reduction: call for action to the cardiology community
Multiple sodium glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1
receptor agonists (GLP-1RA) have been shown to impart significant cardiovascular and …
receptor agonists (GLP-1RA) have been shown to impart significant cardiovascular and …
Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: A real-world population-based analysis
Background Kidney benefits have been demonstrated for both sodium-glucose
cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) …
cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) …
Major advancements in slowing diabetic kidney disease progression: focus on SGLT2 inhibitors
GL Bakris - American Journal of Kidney Diseases, 2019 - ajkd.org
Diabetes is the most common cause of end-stage kidney disease, and its incidence and
prevalence are projected to double by 2030. 1 During the past 3 decades, major studies to …
prevalence are projected to double by 2030. 1 During the past 3 decades, major studies to …
相关搜索
- kidney disease sglt2 inhibitors
- receptor agonists sglt2 inhibitors
- receptor agonists kidney outcomes
- decision algorithm sglt2 inhibitors
- receptor agonists decision algorithm
- kidney disease decision algorithm
- receptor agonists paradigm shift
- receptor agonists medical management
- receptor agonists sodium glucose
- major advancements sglt2 inhibitors
- receptor agonists renal benefits
- receptor agonists real world
- meta analysis sglt2 inhibitors
- kidney disease meta analysis
- kidney outcomes sglt2 inhibitors
- receptor agonists kidney disease